CIVO® Platform

How CIVO Works

In a few simple steps, this patented process can simultaneously evaluate multiple drugs or drug combinations using 100+ assays for tumor and microenvironment responses.

01
CIVO injects drug microdoses directly into a patient's tumor. The device delivers trackable drug "columns."
02
Drugs interact with the tumor while still within the patient. Then the tumor is surgically removed.
03
The tumor tissue is processed by sectioning crosswise to the drug columns. Four-micron sections are then cut and placed onto slides for staining.
04
Tumor slices are assessed for responses around each injection site
05
Responses are quantified and compared between drugs and drug combinations
06
Spatial biology provides deeper insights in the tumor microenvironment and drug response

Civo evaluates clinical response

where it matters most—the patient's tumor

The CIVO (Comparative In Vivo Oncology) platform delivers multiplexed intratumoral microdosing. Analysis of the tumor enables researchers, clinical investigators, and our pharmaceutical collaborators the ability to evaluate localized tumor response to drug candidates in the tumor microenvironment while capturing tumor heterogeneity and patient-specific responses.

FDA, IRB, OR IACUC-Approved Research

CIVO offers a microscopic view of the direct interactions between the investigational assets and the tumor in situ.
Not only are the drug sites simple to identify, but responses are easy to observe, interpret, and are consistent with expected clinical responses.

CIVO Microdose Injections induce anti-tumor immune response

CIVO highlights

Fundamentally changing cancer
drug development

In a few simple steps, this patented process can simultaneously evaluate multiple drugs or
drug combinations using 100+ assays for tumor and microenvironment responses.

01
CIVO injects drug microdoses directly into a patient's tumor. The device delivers trackable drug "columns."
02
Drugs interact with the tumor while still within the patient. Then the tumor is surgically removed.
03
The tumor tissue is processed by sectioning crosswise to the drug columns. Four-micron sections are then cut and placed onto slides for staining.
04
Tumor slices are assessed for response around each injection site using CIVOanalyzer
05
CIVOanalyzer delivers automated response quantification via radial distance calculations, effectively comparing responses between drugs and drug combinations.
06
Spatial biology or how the insights can be applied?

CIVO injects drug microdoses directly into a patient's tumor. The device delivers trackable drug "columns."

Drugs interact with the tumor while still within the patient. Then the tumor is surgically removed.

The tumor tissue is processed by sectioning crosswise to the drug columns. Four-micron sections are then cut and placed onto slides for staining.

Tumor slices are assessed for response around each injection site using CIVOanalyzer

CIVOanalyzer delivers automated response quantification via radial distance calculations, effectively comparing responses between drugs and drug combinations.

CIVO injects drug microdoses directly into a patient's tumor. The device delivers trackable drug "columns."
Drugs interact with the tumor while still within the patient. Then the tumor is surgically removed.
The tumor tissue is processed by sectioning crosswise to the drug columns. Four-micron sections are then cut and placed onto slides for staining.
Tumor slices are assessed for response around each injection site using CIVOanalyzer
CIVOanalyzer delivers automated response quantification via radial distance calculations, effectively comparing responses between drugs and drug combinations.
Previous
Next

Fundamentally changing cancer drug development

In a few simple steps, this patented process can simultaneously evaluate multiple drugs or drug combinations using 100+ assays for tumor and microenvironment responses.

CIVO: designed to solve a long-standing challenge

The importance of designing specialized devices to deliver microdoses to solid tumors in situ has been recognized by lawmakers and researchers alike. Microdosing devices, like CIVO, were recognized by the Moonshot Initiative: “if widely implemented, [it] could revolutionize the way in which drug combinations are tested…”1 and help accelerate early-stage drug development.
"…delivery of cancer drugs directly into tumors in vivo can indicate cancer sensitivity; if implemented in clinical practice, these devices have the potential to reduce indiscriminate drug use, to improve survival, and to reduce unnecessary adverse effects.”2
R. Charles Coombes

Integrating Civo

Streamline Your Oncology Drug Development Strategy

References

Cancer Moonshot Blue Ribbon

Science Translational
Medicine Paper

Integrating Civo

Streamline Your Oncology Drug Development Strategy

References

Cancer Moonshot Blue Ribbon

Science Translational
Medicine Paper